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Intravenous digoxin as a bioavailability standard 
To the Editor: 
In a recent publication in this JOURNAL, 
Greenblatt and associates3 recommended that 
the" administration of digoxin by slow infusion 
is preferable as an intravenous standard in bio-
availability testing" as opposed to a rapid intra-
venous injection. While we do not necessarily 
disagree with this conclusion, we do disagree 
with the reasons cited in their publication to 
support this contention. Because of the likely 
influence an article such as this may have on 
federal regulatory procedures, we would like to 
express our alternative viewpoints as related to 
their study. 
First, the authors demonstrated a statistically 
significant difference in the cumulative amount 
of digoxin excreted in the urine following rapid 
intravenous injection and slow intravenous in-
fusion of 0.75 mg digoxin. In our opinion, this 
difference could well be attributed to the ana-
lytic procedures (i.e., radioimmunoassay) used 
to measure urine digoxin concentrations. More 
specifically, in our studies the digoxigenin-bis-
digitoxoside metabolite of digoxin bound more 
strongly with our antiserum than digoxin it-
self. 5, 6 Since it is likely that a mixture of un-
changed drug and metabolite is being measured 
and it is known that between 5% and 15% of a 
normal dose of digoxin is excreted in the urine 
in the form of metabolites,!' 4 the apparent 
amount of drug measured in the urine could 
vary depending upon the ratio of digoxin to me-
tabolites and the cross-reactivity of their anti-
serum. In our opinion, the data of Greenblatt 
and associates3 showed that the rate of digoxin 
administration does influence the digoxin/me-
tabolite ratio found in urine or serum. Hence, 
when digoxin was administered via the rapid in-
travenous route, less metabolism of the drug 
occurred due to near saturation of certain en-
zyme systems and more free drug was found in 
the urine than when the drug was given by the 
slower intravenous infusion route. The slightly 
greater ratio of metabolite to digoxin that oc-
curred after infusion would be measured as an 
apparently higher output of total digoxin due to 
the cross-reactivity of the antiserum with the 
certain metabolites. The approximately 2% dif-
ference in area under the serum concentration 
curve and 10% difference in the total amount of 
drug excreted in the urine can be accounted for 
in this manner. 
Second, Greenblatt and associates2, 3 have 
indicated that monitoring urinary excretion is a 
more acceptable procedure for the assessment 
of bioavailability for digoxin than using plasma 
or serum concentration parameters. Again, the 
facts (1) that more metabolites may be present 
in the urine than in the blood because of kid-
ney metabolism and the potential further degra-
dation of drug while it resides in the bladder and 
(2) that urine usually provides a higher concen-
tration per unit volume of these materials than 
is usually found in the blood imply that the non-
specificity of the analytic procedures could well 
mask real differences in drug absorption that 
exist from subject to subject. Third, there are 
some real problems from a logistic point of 
view. A simple 2-way crossover design for di-
goxin would require 8 to 12 subjects, and, un-
less all the subjects could be confined for the 
duration of each phase of the study, the reli-
ability of complete urine sample collection for 
such a group of subjects cannot be assured. Lost 
urine samples in our experience are a serious 
problem in an ambulatory subject population, 
and creatinine excretion studies are realistically 
not so accurate that a 10- or 20-rnl sample in-
advertently lost during a peak excretion period 
could be recognized. In blood level studies, of 
course, subject reliability would be less of a 
problem. 
We would also like to point out that, based 
on the half-life of digoxin of 1 V2 days, an appro-
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priately designed blood level study should be 
conducted for at least 96 hr,7 rather than the 0 to 
8 hr design used by Greenblatt and associates.3 
It is recognized that this would require consider-
able modification of existing radioimmunoassay 
procedures, since, as suggested by Greenblatt 
and associates,3 the blood levels go below the 
normal limits of assay 48 hr after a single 0.5-
mg dose. The necessary modifications have, 
however, been published. 6 
Another point to be considered is the desir-
ability of using a I-hr intravenous infusion pro-
cedure as a bioavailability standard. To be con-
ducted accurately, such a procedure requires an 
infusion pump and, from a practical point of 
view, this would be less than desirable for rou-
tine bioavailability testing. An oral solution 
properly prepared represents the optimum 
amount of absorption that could be expected 
from any tablet system and, as long as it is 
recognized that an oral dose is not completely 
equivalent to an intravenous dose, a 100% ab-
sorbed system is not essential for bioavail-
ability testing. 
In conclusion, we do not intend this letter 
to discredit the fine work of Greenblatt and 
associates ,2, 3 but rather it is hoped that the ques-
tions we have raised will be helpful in stimu-
lating further work in this vital area of medicine 
before any far-reaching regulatory procedures 
are implemented. 
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Reply 
To the Editor: 
Drs. Stoll and Wagner present an interesting 
hypothesis to explain our finding that cumula-
tive urinary excretion of immunoassayable dig-
oxin after slow infusion is less than that after 
rapid injection. Further study is needed to sub-
stantiate this hypothesis. It does not influence 
our major point that between-subject variability 
in cumulative urinary excretion after rapid in-
jection is greater than after slow infusion. 
Hence, slow intravenous infusion is preferable 
for bioavaiiability testing even though an infu-
sion pump is required. Digoxin solution given 
by mouth could be used as a standard for com-
parative studies of various tablet preparations. 
However, we have found that between-subject 
variability in bioavailability of digoxin elixir is 
considerably greater than that of intravenous 
digoxin, particularly when blood concentrations 
are used. 1 
The design of a bioavailability study cannot 
be dictated by a single predetermined pharma-
cokinetic parameter. A study is "appropriately 
designed" when it provides useful information. 
A 96-hr blood concentration study does yield 
more data than a 8-hr study. However, since 
digoxin absorption is essentially complete with-
in 8 hr, it is doubtful whether extending the 
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sampling period to 96 hr provides enough addi-
tional useful information to outweigh the in-
creased expense, inconvenience, and discom-
fort. 
Urinary digoxin concentrations are con-
siderably higher than those in serum. In our 
studies three small aliquots (10, 20, and 50 ILl) 
were taken from each urine sample, diluted to 
1.0 ml, and subjected to radioimmunoassay.1 
Urine concentration data were based upon that 
aliquot that fell on the reliable portion of the 
standard curve (1 to 5 ng/mJ). Obviously, uri-
nary excretion studies require subjects who can 
be trusted to provide complete urine collections. 
Such subjects do exist. 
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Concentration of morphine equivalent 
in urine 
To the Editor: 
We were interested by the finding of an ex-
ponential decline in concentration of morphine 
equivalent in urine reported on page 303 of the 
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August, 1974, issue of the JOURNAL by Robin-
son and colleagues, and by their suggestion that 
this is evidence for an active renal mechanism. 
We have noted a similar phenomenon for me-
thaqualone (Table I). Overall, the urine con-
centration data fitted a biexponential curve, 
similar to that reported for methaqualone in the 
same issue of the JOURNAL on page 376 by 
Dr. Clifford and colleagues, and the derived 
data shown in the table agree with those of 
Clifford and of Alvan.1 
The most probable explanation for this corre-
lation between urine concentration and plasma 
concentration for methaqualone is extensive 
tubular reabsorption, renal clearance of about 1 
ml/min, leading to flow-dependent elimination 
by the kidney. We would suggest that our find-
ings and those of Dr. Clifford indicate that 
where renal elimination of drugs is not solely 
by filtration, then urine concentration will par-
allel plasma concentration. 
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Table I. Relationship between log concentration of methaqualone in urine and time* 
Early phase a or f3 (h- 1) p Ti (hr) 
[0-5 hr after administration] 0.36 to 0.48 < 0.01 1.7 
Late phase 
[5-36 hr after administration] 0.014 to 0.026 < 0.01 37 
Time (hr) 2 3 3.5 5 6 7.5 9 22 25 26 
Concentration 0.57 0.41 0.36 0.37 0.28 0.27 0.03 0.18 0.18 0.16 
(jLg/ml) 
* Results are from 3 normal volunteers given an oral dose of 250 mg methaqualone hydrochloride. The regressions of the early and late phases 
(a and {3) were tested by analysis of variance and the p value is shown, together with the average half-life. Also shown are representative 
concentration-time data for 1 subject. 
